William A. Nuerge

Shire US, Inc. sells and markets prescription medicines. The company was founded on September 28, 1983 and is headquartered in Lexington, MA.

Part of Mallinckrodt Plc, Lafayette Pharmaceuticals, Inc. is a company that manufactures barium sulfate contrast agents used in various medical diagnostic imaging procedures. The company is based in Lafayette, IN. Lafayette Pharmaceuticals was acquired by Mallinckrodt, Inc.(Old) from Inovision Holdings LP on December 15, 2000.

Shire Richwood, Inc. manufactures and distributes pharmaceutical products for the treatment of neurological disorders. It offers drugs to treat chronic pain, gastrointestinal problems and attention deficit disorder. The company markets its products through its sales force to physicians, cancer centers, hospice programs and home health care agencies in the United States. It also serves pharmacy chains, managed care plans, hospital purchasing groups and wholesalers. Shire Richwood was founded by Roger D. Griggs in 1990 and is headquartered in Florence, KY.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY.

Shire Laboratories was a specialty pharmaceutical company focused on developing products for its own portfolio and in partnership with other companies, using its technologies and development capabilities. The company products include CollaGenex, Indevus, Shire and United Therapeutics. Its key technologies are ProScreen, OptiScreen , Microtrol, Solutrol and EnSoTrol, for bioavailability enhancement and oral controlled release, and Avert for reduced-abuse potential. Shire Laboratories was headquartered in Rockville, MD.

Part of Gemini Strategies LLC, Inc., Cutanogen Corp. is a company that develops artificial skin products used to treat patients with severe burns. The company is based in Cincinnati, OH. The CEO of the company is Gerald E. Commissiong. Cutanogen was acquired by Amarantus Bioscience Holdings, Inc. from Lonza Group AG on July 15, 2015 for $9 million.